A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial ID NCT00556322

Rank	Title	Journal	Year	PubWeight™‹?›
1	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.	Lancet Oncol	2012	4.15
2	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nat Rev Clin Oncol	2010	2.26
3	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	J Clin Oncol	2015	1.67
4	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.	J Cancer	2013	1.31
5	Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.	J Med Chem	2010	1.02